237 related articles for article (PubMed ID: 21319020)
1. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
4. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
5. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Ito C; Aisa Y; Mihara A; Nakazato T
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):83-5. PubMed ID: 23103083
[No Abstract] [Full Text] [Related]
7. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
9. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
10. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
11. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
13. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
16. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
[No Abstract] [Full Text] [Related]
18. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Pirrotta MT; Gozzetti A; Cerase A; Bucalossi A; Bocchia M; Defina M; Lauria F
Onkologie; 2008 Feb; 31(1-2):45-7. PubMed ID: 18268398
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
20. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
